Search This Blog

Thursday, January 3, 2019

Neon Therapeutics expects to fund operating expenses, cap-ex into 2020

  Based on its current operating plans, Neon now expects that its existing cash, cash equivalents and marketable securities will enable the company to fund its anticipated operating expenses and capital expenditure requirements into Q2 of 2020. As of September 30, 2018, Neon had $121.7M in cash, cash equivalents and marketable securities. 
https://thefly.com/landingPageNews.php?id=2843021

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.